4.7 Article

A Novel Topical Fluorescent Probe for Detection of Glioblastoma

期刊

CLINICAL CANCER RESEARCH
卷 27, 期 14, 页码 3936-3947

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-4518

关键词

-

类别

资金

  1. Translational Research Program
  2. Strategic Promotion for Practical Application of Innovative Medical Technology (TR-SPRINT) from Japan Agency for Medical Research and Development (AMED) [A105]
  3. Japan Society for the Promotion of Science [15K19952, 20K09365]
  4. AMED Practical Research for Innovative Cancer Control [20ck0106578h0001]
  5. Grants-in-Aid for Scientific Research [15K19952, 20K09365] Funding Source: KAKEN

向作者/读者索取更多资源

The study developed a novel fluorescent probe PR-HMRG that can be repeatedly administered as a topical spray during surgery for effective detection of glioblastoma. Further investigations are needed to evaluate its clinical efficacy and safety.
Purpose: Five-aminolevulinic acid (5-ALA) is widely used as an intraoperative fluorescent probe for radical resection of high-grade glioma, and thus aids in extending progression-free survival of patients. However, there exist some cases where 5-ALA fails to fluoresce. In some other cases, it may undergo fluorescence quenching but cannot be orally readministered during surgery. This study aimed to develop a novel hydroxymethyl rhodamine green (HMRG)-based fluorescence labeling system that can be repeatedly administered as a topical spray during surgery for the detection of glioblastoma. Experimental Design: We performed a three-stage probe screening using tumor lysates and fresh tumor tissues with our probe library consisting of a variety of HMRG probes with different dipeptides. We then performed proteome and transcript expression analyses to detect candidate enzymes responsible for cleaving the probe. Moreover, in vitro and ex vivo studies using U87 glioblastoma cell line were conducted to validate the findings. Results: The probe screening identified proline-arginine-HMRG (PR-HMRG) as the optimal probe that distinguished tumors from peritumoral tissues. Proteome analysis identified calpain-1 (CAPN1) to be responsible for cleaving the probe. CAPN1 was highly expressed in tumor tissues which reacted to the PR-HMRG probe. Knockdown of this enzyme suppressed fluorescence intensity in U87 glioblastoma cells. In situ assay using a mouse U87 xenograft model demonstrated marked contrast of fluorescence with the probe between the tumor and peritumoral tissues. Conclusions: The novel fluorescent probe PR-HMRG is effective in detecting glioblastoma when applied topically. Further investigations are warranted to assess the efficacy and safety of its clinical use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据